Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease
Eterna Therapeutics has announced its rebranding to Ernexa Therapeutics (NASDAQ: ERNA), marking a strategic shift from a cell therapy platform to focused product development in ovarian cancer and autoimmune disease treatments. The company's technology specializes in transforming induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), which can target tumors and inflammation.
Two key products are currently in preclinical trials: ERNA-101, engineered to enhance immune response against cancer cells, specifically targeting ovarian cancer as its first indication, and ERNA-102, designed to combat inflammation and treat autoimmune disease. The company aims to address significant unmet needs, particularly in ovarian cancer treatment, where current platinum-based chemotherapy often faces resistance issues.
Eterna Therapeutics ha annunciato il suo rebranding in Ernexa Therapeutics (NASDAQ: ERNA), segnando un cambiamento strategico da una piattaforma di terapia cellulare a uno sviluppo di prodotti focalizzato nel trattamento del cancro ovarico e delle malattie autoimmuni. La tecnologia dell'azienda si specializza nella trasformazione delle cellule staminali pluripotenti indotte (iPSCs) in cellule staminali mesenchimali indotte (iMSCs), in grado di colpire tumori e infiammazioni.
Due prodotti chiave sono attualmente in fase di sperimentazione preclinica: ERNA-101, progettato per migliorare la risposta immunitaria contro le cellule tumorali, con un focus specifico sul cancro ovarico come prima indicazione, e ERNA-102, concepito per combattere l'infiammazione e trattare le malattie autoimmuni. L'azienda mira a soddisfare esigenze significative non soddisfatte, in particolare nel trattamento del cancro ovarico, dove la chemioterapia attuale a base di platino spesso affronta problemi di resistenza.
Eterna Therapeutics ha anunciado su cambio de marca a Ernexa Therapeutics (NASDAQ: ERNA), marcando un cambio estratégico de una plataforma de terapia celular a un desarrollo de productos enfocado en el tratamiento del cáncer de ovario y enfermedades autoinmunes. La tecnología de la empresa se especializa en transformar células madre pluripotentes inducidas (iPSCs) en células madre mesenquimatosas inducidas (iMSCs), que pueden atacar tumores e inflamaciones.
Dos productos clave se encuentran actualmente en ensayos preclínicos: ERNA-101, diseñado para mejorar la respuesta inmune contra las células cancerosas, enfocándose específicamente en el cáncer de ovario como su primera indicación, y ERNA-102, concebido para combatir la inflamación y tratar enfermedades autoinmunes. La empresa tiene como objetivo abordar necesidades significativas no satisfechas, particularmente en el tratamiento del cáncer de ovario, donde la quimioterapia actual basada en platino a menudo enfrenta problemas de resistencia.
이터나 테라퓨틱스는 에르넥사 테라퓨틱스 (NASDAQ: ERNA)로의 브랜드 변경을 발표하며, 세포 치료 플랫폼에서 난소암 및 자가면역 질환 치료에 집중하는 제품 개발로의 전략적 전환을 알렸습니다. 이 회사의 기술은 유도 다능성 줄기세포(iPSCs)를 유도 중간엽 줄기세포(iMSCs)로 변환하는 데 전문화되어 있으며, 이는 종양과 염증을 표적으로 할 수 있습니다.
현재 두 가지 주요 제품이 전임상 시험 중입니다: ERNA-101, 암세포에 대한 면역 반응을 강화하도록 설계되었으며, 첫 번째 적응증으로 난소암을 목표로 하고 있고, ERNA-102, 염증을 억제하고 자가면역 질환을 치료하기 위해 설계되었습니다. 이 회사는 특히 난소암 치료에서의 현재 백금 기반 화학요법이 자주 저항성 문제에 직면하는 등, 충족되지 않은 중요한 필요를 해결하는 것을 목표로 하고 있습니다.
Eterna Therapeutics a annoncé son changement de marque en Ernexa Therapeutics (NASDAQ: ERNA), marquant un changement stratégique d'une plateforme de thérapie cellulaire vers un développement de produits axé sur le traitement du cancer de l'ovaire et des maladies auto-immunes. La technologie de l'entreprise se spécialise dans la transformation de cellules souches pluripotentes induites (iPSCs) en cellules souches mésenchymateuses induites (iMSCs), capables de cibler les tumeurs et l'inflammation.
Deux produits clés sont actuellement en phase d'essai préclinique : ERNA-101, conçu pour améliorer la réponse immunitaire contre les cellules cancéreuses, ciblant spécifiquement le cancer de l'ovaire comme première indication, et ERNA-102, conçu pour lutter contre l'inflammation et traiter les maladies auto-immunes. L'entreprise vise à répondre à des besoins non satisfaits significatifs, en particulier dans le traitement du cancer de l'ovaire, où la chimiothérapie actuelle à base de platine est souvent confrontée à des problèmes de résistance.
Eterna Therapeutics hat sein Rebranding zu Ernexa Therapeutics (NASDAQ: ERNA) angekündigt, was einen strategischen Wechsel von einer Zelltherapie-Plattform hin zu einer fokussierten Produktentwicklung im Bereich der Behandlung von Eierstockkrebs und Autoimmunerkrankungen markiert. Die Technologie des Unternehmens spezialisiert sich auf die Umwandlung von induzierten pluripotenten Stammzellen (iPSCs) in induzierte mesenchymale Stammzellen (iMSCs), die Tumore und Entzündungen angreifen können.
Derzeit befinden sich zwei Schlüsselprodukte in der präklinischen Erprobung: ERNA-101, das entwickelt wurde, um die Immunantwort gegen Krebszellen zu verstärken, wobei der Schwerpunkt auf Eierstockkrebs als erste Indikation liegt, und ERNA-102, das zur Bekämpfung von Entzündungen und zur Behandlung von Autoimmunerkrankungen konzipiert wurde. Das Unternehmen zielt darauf ab, bedeutende unbefriedigte Bedürfnisse zu adressieren, insbesondere in der Behandlung von Eierstockkrebs, wo die derzeitige platinbasierte Chemotherapie häufig auf Resistenzprobleme stößt.
- None.
- None.
Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing product development
New tagline to emphasize the company’s unwavering commitment to patient impact,
“Breaking Through Defenses, Delivering Hope”
CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics, a leader in cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the company’s new name: Ernexa TherapeuticsSM (NASDAQ: ERNA). The new name reflects the company’s laser-focused mission and ambitious vision.
“Eterna Therapeutics began as a pioneer developing an innovative and differentiated cell therapy platform alone, but today, we have entered a new era of evolution and growth,” said Sanjeev Luther, President and CEO of Ernexa Therapeutics. “We are an organization with a new strategic focus, one that is advancing transformative cell therapy products with real clinical potential, directly impacting patients’ lives and addressing unmet medical needs.”
Ernexa’s technology transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), which are a specialized type of stem cell that has a unique ability to migrate toward tumors or inflammation. Ernexa’s allogeneic synthetic iMSCs allow for enhanced predictability at scale, helping to avoid the challenges of immune rejection and donor shortages.
Ernexa has two cell therapy products in development, which are undergoing preclinical trials. Its lead cell therapy product, ERNA-101, is engineered to enhance and regulate the immune system’s response, enabling it to identify and eliminate cancer cells. ERNA-102 is designed to combat inflammation and treat autoimmune disease.
ERNA-101 is being developed for the treatment of ovarian cancer as its first indication. There is a significant unmet need in ovarian cancer, which currently lacks highly effective, widely applicable targeted therapies. Many patients develop resistance to the standard treatment in ovarian cancer – platinum-based chemotherapy. Other treatments have been developed but with little success.
ERNA-101 and ERNA-102 have the potential to bring significant hope in the treatments of ovarian cancer and autoimmune disease, respectively.
Ernexa’s ticker symbol will remain as ERNA.
About Ernexa Therapeutics
Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.
Ernexa is developing two highly innovative cell therapy products, both currently in preclinical stages. ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system’s response to recognize and attack cancer cells. ERNA-102 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.
For more information, visit www.ernexatx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "objective," or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa Therapeutics’ actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: progress and possible outcomes of the Company’s lead research project, ERNA-101, and future research projects. Forward-looking statements are based upon Ernexa's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa's risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K, and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law.
Media & Investor Relations Contact
FAQ
What are the main products in Ernexa Therapeutics (ERNA) development pipeline?
How does Ernexa Therapeutics (ERNA) technology work with stem cells?
Why is Ernexa Therapeutics (ERNA) focusing on ovarian cancer treatment?
What is the significance of Eterna Therapeutics changing its name to Ernexa (ERNA)?
What advantages does Ernexa's (ERNA) allogeneic synthetic iMSC technology offer?
